Silence Therapeutics Plc American Depository Share (SLN)
Nasdaq: SLN · Pharmaceutical Preparations · London · filing with the SEC since 2010
Who runs Silence Therapeutics Plc American Depository Share
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedOfficers reporting now
3
of 6 people with a filing in the last fifteen months
Directors reporting now
3
8 people on the record since 2025
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Hellums Rhonda Lynette | Chief Financial Officer | Jan 2025 | Jan 6, 2026 | none |
| Romano Steven J. | EVP and Chief R&D Officer | Jan 2025 | Jan 6, 2026 | none |
| Ross Iain | Interim PEO | Jan 2025 | Dec 22, 2025 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Ede-Golightly James | director | Jan 2025 | Jan 6, 2026 | none |
| Lemus David | director | Jan 2025 | Jan 6, 2026 | none |
| Mcinerney Timothy | director | May 2025 | Jan 6, 2026 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Griffiths Richard Ian | 10% owner | Jan 2025 | Aug 13, 2026 | none |
Earlier names on the record2, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.